Clinical Trial Update: Personalized Neoantigen Peptide Vaccines for Solid Tumors [Phase 1, Phase 2]

View source ↗

Summary

Seqker Biosciences is running a Phase 1/Phase 2 trial of personalized neoantigen peptide vaccines for solid tumors, currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Solid Tumors

Snippet

Sponsor: Seqker Biosciences, Inc. | Conditions: Solid Tumors, Advanced Cancer | Phase 1, Phase 2 | Status: RECRUITING